appScorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Aarti Pharmalabs Ltd
AARTIPHARM
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Price
Price Upside
—
Earnings
Earnings Growth
—
Revenue
Rev. Growth
—
Company Profile
Aarti Pharmalabs Ltd manufactures active pharmaceutical ingredients and intermediates, offering CDMO services for drug development and production, with a focus on oncology and corticosteroid products.
PeersCompare with peers
Divi's Laboratories Ltd
Syngene International Ltd
Dishman Carbogen Amcis Ltd
Vimta Labs Ltd
Brooks Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
Hmm, looks like data is unavailable here. Please come back after some timeRecent EventsAll events
Board Meeting Intimation
AARTI PHARMALABS LIMITED has informed the Exchange about Board Meeting to be held on 05-Feb-2025 to consider and approve the Quarterly Audited Financial results of the Company for the period ended December 2024 and Dividend/Other business. | Download
AARTI PHARMALABS LIMITED has informed the Exchange about Board Meeting to be held on 05-Feb-2025 to consider and approve the Quarterly Audited Financial results of the Company for the period ended December 2024 and Dividend/Other business. | Download
Cash Dividend
Final • Div/Share: ₹ 1
Decreased Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 1.81%